<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109954</url>
  </required_header>
  <id_info>
    <org_study_id>PCI-04128</org_study_id>
    <secondary_id>CDR0000425333</secondary_id>
    <secondary_id>PCI-IRB-0501021</secondary_id>
    <nct_id>NCT00109954</nct_id>
  </id_info>
  <brief_title>Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing. In this&#xD;
      case, chemotherapy is given through the artery (hepatic artery) that brings blood to the&#xD;
      tumor. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and&#xD;
      keeping chemotherapy drugs near the tumor. Internal radiation uses radioactive material&#xD;
      placed directly into or near a tumor to kill tumor cells. It is not yet known whether hepatic&#xD;
      arterial chemoembolization with cisplatin is more effective than internal radiation therapy&#xD;
      in treating liver cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying hepatic arterial chemoembolization with&#xD;
      cisplatin to see how well it works compared to internal radiation therapy in treating&#xD;
      patients with advanced liver cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare time to disease progression in patients with unresectable advanced&#xD;
           hepatocellular carcinoma treated with cisplatin-based trans-arterial chemoembolization&#xD;
           vs hepatic intra-arterial yttrium Y 90 glass microspheres (TheraSphere®).&#xD;
&#xD;
        -  Compare the health-related quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare tumor response by CT scan in patients treated with these regimens.&#xD;
&#xD;
        -  Compare treatment-related costs, in terms of cost of therapy and number of&#xD;
           hospitalization days, in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to extent of tumor in&#xD;
      the liver (&lt; 50% vs ≥ 50%) and presence of portal hypertension (yes vs no). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo trans-arterial chemoembolization comprising intra-arterial (IA)&#xD;
           infusion of cisplatin over 30-60 minutes followed by embolization of the hepatic artery&#xD;
           (that brings blood to the tumor) on day 1. Treatment repeats every 8-10 weeks in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive yttrium Y 90 glass microspheres (TheraSphere®) IA on day 1.&#xD;
           Beginning 60 days after the first TheraSphere® treatment, patients may receive&#xD;
           additional treatment with TheraSphere® only if follow-up CT scans show progressive&#xD;
           disease.&#xD;
&#xD;
      Quality of life is assessed at baseline and then every 3 months thereafter.&#xD;
&#xD;
      After the completion of study treatment, patients are followed at 30 days and then every 2&#xD;
      months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival as assessed by tumor progression in the treated lobe of the liver</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life at baseline and every 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as measured by NCI CTCAE version 3.0</measure>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 glass microspheres</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Histologically or cytologically confirmed hepatocellular carcinoma (HCC)&#xD;
&#xD;
                    -  Confined to the liver&#xD;
&#xD;
               -  Vascular liver mass in the presence of cirrhosis&#xD;
&#xD;
                    -  Alpha-fetoprotein level &gt; 500 ng/mL&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion &gt; 20 mm by spiral CT scan&#xD;
&#xD;
          -  Unresectable disease, due to tumor size or extent or presence of cirrhosis&#xD;
&#xD;
          -  No metastatic disease, including brain metastases&#xD;
&#xD;
               -  Locoregional lymph node metastases allowed&#xD;
&#xD;
          -  No evidence of potential delivery of &gt; 16.5 miCi (30 Gy absorbed dose) of radiotherapy&#xD;
             to the lungs either during the first administration of yttrium Y 90 glass microspheres&#xD;
             (TheraSphere®) or on cumulative delivery of radiation to the lungs over multiple&#xD;
             treatments*&#xD;
&#xD;
          -  No evidence of detectable technetium Tc 99m macroaggregated albumin (Tc-99m MAA) flow&#xD;
             to the stomach or duodenum after application of established angiographic techniques to&#xD;
             stop the flow* NOTE: *For patients randomized to the TheraSphere® arm only&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 60,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis not correctable by usual forms of therapy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  AST and/or ALT ≤ 5 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis allowed&#xD;
&#xD;
          -  No portal hypertension with hepatofugal flow&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No severe peripheral vascular disease that would preclude catheterization&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double barrier or hormonal contraception during&#xD;
             and for at least 30 days after completion of study treatment&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior systemic chemotherapy for HCC&#xD;
&#xD;
          -  More than 4 weeks since prior IV chemotherapy and recovered&#xD;
&#xD;
          -  More than 1 year since prior hepatic arterial cisplatin&#xD;
&#xD;
          -  More than 4 months since other prior hepatic arterial chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior external hepatic radiotherapy for HCC&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent therapy for HCC&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian I. Carr, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Weijing Sun, MD, FACP</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

